The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / Articles / August / From Training Burden to Training Value 
Business & Regulation Development & Clinical Regulation & Standards Business & Trends Technology & Manufacturing Sponsored

From Training Burden to Training Value 

Why effective study training depends on relevance, timing, and oversight.

08/14/2026 0 min read Interview

Share

Study training is essential to clinical trial compliance, but assigning, tracking, and documenting it across global studies can consume time better spent improving training quality and impact. Reducing that burden helps ensure that each person receives the right training at the right time.

Tine De Pla of Amgen and Aidan Gannon of Veeva Systems discuss how role-based automation can strengthen oversight, reduce unnecessary training, and deliver more timely, useful learning. They also explore the links between effective training, patient safety, trial execution, and data quality.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: John Maher
Cell & Gene Power List Development & Clinical
Musings from The Power List: John Maher

August 14, 2026

4 min read

John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors

From Training Burden to Training Value 
Development & Clinical Regulation & Standards Business & Trends
From Training Burden to Training Value 

August 14, 2026

0 min read

Why effective study training depends on relevance, timing, and oversight.

Why Cell Therapy Needs a Digital Backboned
Cell & Gene Development & Clinical Interviews
Why Cell Therapy Needs a Digital Backbone

August 13, 2026

8 min read

Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional

What Did ASCO 2026 Reveal About the Future of Oncology?
Development & Clinical Future of Pharma Technology & Manufacturing
What Did ASCO 2026 Reveal About the Future of Oncology?

August 6, 2026

8 min read

Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: